Health Trials

Lupus Nephritis - WHO Class III

2

Review clinical trials related to Lupus Nephritis - WHO Class III. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis

The primary objective of this trial is to evaluate the efficacy and safety of FT819, comprised of allogeneic T cells that express a CD19-targeted CAR, following bendamustine administration in participants with refractory moderate-to-severe lupus nephritis, as assessed by the proportion of participants who achieve complete renal response (CRR) at Week 26.

Participants needed: 53
Trial details
Phase: Phase 2Age: 12-70Biological sex: AllType: InterventionalSponsor: Fate TherapeuticsUpdated: May 11, 2026
Eligibility criteria

Age ≥12 to ≤70 years [+6]

Evidence of inadequate organ function during the screening period [+9]

Read more
Status: Recruiting

Safety and Efficacy of ONT01 in Lupus

ONT01 is a drug that is being studied for the treatment of Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) and is not approved by the FDA. The purpose of this study is to better determine whether ONT01 is safe and tolerated by people with lupus nephritis or SLE. The study also looks at how the administration of ONT01 in combination with widely used treatments given for lupus, including the medication mycophenolate mofetil and others, can improve symptoms of lupus. A total of 61 participants will be enrolled in this study.

Participants needed: 61
Trial details
Phase: Early Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Hospital for Special Surgery, New YorkUpdated: Nov 20, 2025Locations: 1
Eligibility criteria

≥ 18 years old and able to provide informed consent to participate. [+6]

Any condition, including any uncontrolled disease (eg, asthma, interstitial lung... [+20]

Read more